Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (LLY 0.35%) and Pfizer (PFE 0.96%).When the COVID-19 pandemic began in 2020, Pfizer quickly emerged as the leader in the race to develop a vaccine. It ultimately raked in billions of dollars in sales for the first approved COVID-19 vaccine. Pfizer also made a fortune with its oral COVID-19 therapy, Paxlovid.Eli Lilly now ranks as the largest drugmaker in the world based on market cap. Its remarkable rise h ...

In a previous article on Seeking Alpha, I presented you with 10 companies that I consider to be attractive investment options for this month of November 2024.I specialize in constructing investment portfolios aimed at generating additional income through dividends. My focus lies on identifying companies with significant competitive advantages and strong financials that can provide you with an attractive Dividend Yield and Dividend Growth, thus enabling you to augment your dividend income annually. By combin ...

On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions.ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational small-molecule stabilizer of transthyretin (TTR) gene.Also Read: BridgeBio Pharma’s Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart DiseaseThe OLE study involves 330 par ...

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible Trump-era tariffs could complicate the Fed's plans, several blue-chip dividend powerhouses like AT&T and Altria have been outperforming the S&P 500 this year.MO data by YChartsTwo high-yield stocks keep drawing my investment dollars in this market. Here's why these two high-yield dividend stocks deserve a closer look from income and value investors with a long-term outlook. Big pharma' ...

Pfizer Inc. PFE shares are lower on Thursday due to news that President-elect Donald Trump picked Robert F. Kennedy Jr. as his next secretary of the Department of Health and Human Services. This has some investors concerned because Kennedy was critical of certain vaccines and vaccinations.Some believe the weakness in the stock may present a buying opportunity. This is why our team of expert traders and technical analysts has made it our Stock of the Day.On Wall Street, many trading strategies and methods ar ...

Zacks Premium and Style Scores Overview - Zacks Premium provides tools for investors to make informed decisions, including daily updates of Zacks Rank, Zacks Industry Rank, Equity Research reports, and Premium stock screens [1] - Zacks Style Scores are complementary indicators that help investors select stocks likely to outperform the market over the next 30 days, with ratings from A (best) to F (worst) [2] Style Score Categories - **Value Score**: Identifies undervalued stocks using metrics like P/E, PEG, Price/Sales, and Price/Cash Flow ratios [3] - **Growth Score**: Focuses on a company's future prospects and financial health, analyzing projected and historic earnings, sales, and cash flow [3] - **Momentum Score**: Helps investors capitalize on price or earnings trends by evaluating factors like one-week price change and monthly earnings estimate revisions [4] - **VGM Score**: Combines Value, Growth, and Momentum Scores to identify stocks with the most attractive value, growth potential, and momentum [5] Zacks Rank and Style Scores Integration - Zacks Rank uses earnings estimate revisions to rate stocks, with 1 (Strong Buy) stocks delivering an average annual return of +25.41% since 1988, outperforming the S&P 500 [6][7] - Investors should prioritize stocks with a Zacks Rank 1 or 2 and Style Scores of A or B for the highest likelihood of success [8] - Stocks with a 4 (Sell) or 5 (Strong Sell) rank, even with high Style Scores, are likely to underperform due to downward-trending earnings forecasts [9] Case Study: Pfizer (PFE) - Pfizer operates in the biopharmaceutical industry, with a focus on Primary Care, Specialty Care, and Oncology [10] - PFE holds a Zacks Rank 2 (Buy) and a VGM Score of A, supported by a Value Style Score of A and a forward P/E ratio of 9.03 [10][11] - Nine analysts revised their earnings estimates upwards for fiscal 2024, increasing the Zacks Consensus Estimate by $0.26 to $2.88 per share, with an average earnings surprise of 74.5% [11]

Pfizer Inc. (NYSE:PFE) UBS Global Healthcare Conference November 13, 2024 3:30 PM ET Company Participants Aamir Malik - Chief Commercial Officer US Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think we’re at the half hour. So good afternoon, everyone. My name is Trung Huynh. I’m the large-cap pharma analyst here at UBS. It’s my great pleasure to introduce Aamir Malik, Chief Commercial Officer for the U.S. for Pfizer. Welcome. Thank you for coming. Aamir Malik Thank you. Thanks f ...

Company and Industry Overview * **Company**: Pfizer Inc. (NYSE:PFE) * **Industry**: Biopharmaceuticals, Pharmaceuticals Key Points and Arguments 1. **Year-to-Date Performance**: * Pfizer has had a strong year, with a particularly strong third quarter. * The company has made progress on several key priorities, including: * Establishing world-class leadership in Oncology through the successful integration of Seagen. * Advancing its pipeline, with good momentum in both oncology and non-oncology areas. * Accelerating the growth of new products, with strong momentum across a wide range of products. * Expanding margins, on track to deliver the expected $4 billion in net savings. * Allocating shareholder capital effectively, with a commitment to growing dividends and deleveraging. * The company has continued to make progress against these priorities every quarter. 2. **New Role for Aamir Malik**: * Malik recently took on the role of Chief U.S. Commercial Officer, with a focus on: * Ensuring the right team is in place. * Managing the U.S. primary care and specialty care business. * Managing global platforms of access, medical, and marketing. * Prioritizing products and allocating resources effectively. * Driving growth across the portfolio. 3. **COVID-19 Business**: * Pfizer's COVID-19 business is becoming more stable and normal. * COMIRNATY has achieved strong market share, with 60% in retail and greater than 60% in non-retail. * PAXLOVID has seen high utilization during outbreaks, with a treatment rate of 57% this year compared to 50% last year. 4. **Pipeline and Pipeline Priorities**: * Pfizer has a rich pipeline of products, with several key assets: * Breast and thoracic cancer ADCs and small molecules. * Ponsegromab for cancer cachexia and heart failure. * Vaccines, including fourth- and fifth-generation PCV vaccines, Lyme disease, C. diff, and strep b maternal vaccines. * Obesity treatment, with a focus on the DANUBE study. 5. **IRA and Pipeline Decisions**: * IRA will have a mixed impact on Pfizer's portfolio, with both pushes and pulls. * The company is managing the impact of IRA through various strategies, including: * Prioritizing pipeline decisions based on the 9-year and 13-year dynamics. * Investing in large molecule drugs. * Managing the impact of IRA on individual products. 6. **Product Performance**: * Seagen has been a successful acquisition, with strong performance and a rich pipeline of products. * Prevnar PCV20 has achieved strong market share in the pediatric market, with 83% market share in September. * RSV vaccines have seen challenges, but Pfizer has executed well and is well positioned for future growth. * ABRYSVO maternal has seen strong uptake, with 20% in the eligible population. 7. **Divestment and Business Development**: * Pfizer is always evaluating its portfolio and considering divestment opportunities. * The company is committed to a growing dividend. * Pfizer will continue to be active in business development, focusing on capital-light deals in the short term. Additional Important Points * Pfizer is committed to pro-innovation and pro-patient policies. * The company is advocating for PBM reform to ensure appropriate access for patients. * Pfizer is well positioned for future growth, with a strong pipeline and a focus on executing effectively.

Pfizer (PFE) has been on a downward spiral lately with significant selling pressure. After declining 11% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is ov ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...